Clinical Trials Logo

Cancer of the Breast clinical trials

View clinical trials related to Cancer of the Breast.

Filter by:

NCT ID: NCT01766297 Recruiting - Breast Cancer Clinical Trials

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

Start date: February 2013
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. A clinical study is necessary to compare the results (good or bad) of proton radiation therapy.

NCT ID: NCT01758445 Active, not recruiting - Breast Cancer Clinical Trials

Proton Radiation for Stage II/III Breast Cancer

Start date: February 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to look at the rates of acute and long term adverse events of postoperative proton radiotherapy for complex loco-regional irradiation in women with loco-regionally advanced breast cancer. This study specifically includes longitudinal follow up to assess the incidence of cardiac mortality and second malignant neoplasms at 10 and 15 years following proton therapy(PT).

NCT ID: NCT01498588 Terminated - Breast Cancer Clinical Trials

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Start date: November 2011
Phase: Phase 2
Study type: Interventional

Previous studies have shown that chemotherapy has the same effect on treating breast cancer whether you receive it before or after surgery. Receiving chemotherapy before surgery, rather than after surgery, may allow the patient to have less extensive surgery. The purpose of this study is to identify new treatment regimens with better response rates and to find out if the combination of eribulin followed by doxorubicin and cyclophosphamide can shrink the size of the patient's breast tumor and allow you to preserve your breast. Additionally, by receiving chemotherapy before surgery, the investigators will be able to determine if your cancer is responsive to chemotherapy.

NCT ID: NCT01272141 Terminated - Breast Cancer Clinical Trials

A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer

Start date: December 2010
Phase: Phase 2
Study type: Interventional

The patient is being asked to join this clinical research study to find out if lapatinib, an agent that targets a protein, called epidermal growth factor receptor (EGFR) on the surface of cancer cells in combination with everolimus, an agent that targets a protein in the cancer cell, called mammalian target of rapamycin (mTOR) is effective in metastatic triple negative breast cancers that are no longer controlled by standard chemotherapy.

NCT ID: NCT01271738 Completed - Breast Cancer Clinical Trials

Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer

Start date: September 2009
Phase: N/A
Study type: Interventional

The goal of this study is to compare two different types of breast surgery. In the first type, the doctor removes only the tumor. In the second type, the doctor removes the tumor and some of the tissue around the tumor called margins. The amount of breast tissue removed is similar. The removal of the tumor only has up to 40% chance of reoperation because the tumor is too close to the margin. The primary goal of this study is to see if the additional margins can decrease the need to return to the operating room. Both types of surgery are well accepted, and participating in the study would not give you a better chance to cure the cancer. At present, most breast surgeons remove the tumor without the additional margins. For all patients who have this operation, there is a high incidence of return to the operating room for margins re-excision: as many as 40% as patients can have a re-operation. At present, we do not know if taking the additional margins prevents the cancer from returning in the breast or not. If the cancer comes back in your breast, this is a recurrence and your breast will have to be removed (mastectomy).

NCT ID: NCT01118624 Completed - Breast Cancer Clinical Trials

Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer

Start date: March 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy (ability to provide a beneficial treatment of the disease) of pralatrexate for the treatment of female patients with advanced or metastatic breast cancer who have failed prior chemotherapy. Patients will receive vitamin B12 and folic acid supplementation.

NCT ID: NCT00832338 Terminated - Breast Cancer Clinical Trials

Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores

Start date: April 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess if docetaxel and cytoxan can shrink the size of your breast tumor and allow you to preserve your breast or have less extensive surgery on your breast. Additionally, by receiving chemotherapy before surgery, the investigators will be able to determine if your cancer is responsive to chemotherapy.

NCT ID: NCT00817362 Terminated - Breast Cancer Clinical Trials

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

Start date: March 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if IPI-504 in combination with trastuzamab is an effective treatment in HER2 positive metastatic breast cancer

NCT ID: NCT00661531 Terminated - Breast Cancer Clinical Trials

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

Start date: April 2008
Phase: Phase 2
Study type: Interventional

This trial seeks to confirm the response rate for estrace treatment in a patients with hormone receptor positive metastatic breast cancer heavily pre-treated with modern endocrine therapies.

NCT ID: NCT00573495 Completed - Breast Cancer Clinical Trials

Multipeptide Vaccine for Advanced Breast Cancer

Start date: November 2007
Phase: Phase 1
Study type: Interventional

This is a study on how to activate the immune system with a vaccine. The vaccine is made up of two proteins found in breast cancer: telomerase and survivin. The vaccine is given in combination with other drugs that may also have an effect on the immune system and attack the cancer. The goals of the study are: 1. to test the safety of the combination of agents 2. to find out what effects the treatment has on advanced breast cancer